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Abstract  1 
Background: Metabolic disorders in midlife increase risk for Alzheimer’s disease (AD). 2 
Dysfunction in insulin signaling is suspected to increase the formation of Aβ42 peptides and is 3 
thought to be associated with impaired memory function. Insulin resistance (IR) observed in 4 
midlife prior to indication of neurodegeneration and cognitive decline is a candidate risk factor 5 
that can be modified by targeted interventions. Regulation of normal insulin function, as a 6 
modifiable risk factor, may be important in reducing the prevalence of AD, particularly in 7 
individuals who harbor a genetic risk or have a parental family history of AD. The relationship 8 
between IR and AD pathology remains poorly understood, particularly at the preclinical stage of 9 
the disease. 10 
 11 
Objective: The objective of the current study was to examine whether IR is associated with 12 
increased AD pathology and decreased memory performance in asymptomatic middle-aged 13 
adults enriched for AD (i.e. with a parental family history of sporadic late-onset AD). We 14 
postulated that IR would be associated with greater AD pathology, particularly in carriers of the 15 
APOE ε4 allele, and poorer memory performance.  16 
 17 
Method: Asymptomatic middle-aged adults with a parental family history of AD (N=70, mean 18 
age=57.7 years) from the Wisconsin Alzheimer’s Disease Research Center underwent lumbar 19 
puncture, blood draw and neuropsychological testing. Cerebrospinal fluid (CSF) samples were 20 
assayed for AD related biomarkers including soluble amyloid precursor protein β (sAPP-β), 21 
abeta42 (Aβ42) and phosphorylated tau (P-tau181). The ratio P-tau181/Aβ42 was also examined as a 22 
more sensitive measure of AD pathology with respect to APOE ε4 status, IR and memory 23 
function. IR was indexed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-24 
IR). Data were analyzed using linear regression models to determine significant effects of IR and 25 
APOE ε4 on CSF biomarkers of AD and memory performance.  26 
 27 
Results: Both APOE ε4 carriage and higher IR were associated with higher sAPP-β. APOE ε4 28 
carriers were observed to have significantly higher levels of AD pathology (P-tau181/Aβ42) 29 
compared to non-carriers.  Investigation of memory performance revealed that higher IR and the 30 
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concurrent presence of AD pathology (P-tau181/Aβ42) were associated with worse delayed 31 
memory performance.  32 
 33 
Conclusion: The current study provides evidence that IR in middle age is associated with higher 34 
sAPP-β, a soluble marker of amyloidogenic APP-processing. Further, these results reveal that IR 35 
and AD pathology concomitantly result in subclinical memory impairment in asymptomatic 36 
middle-aged individuals enriched for AD. Lastly, these findings converge with prior studies 37 
indicating that APOE ε4 carriage is associated with increased AD pathology that can be observed 38 
in early aging prior to the onset of clinical memory impairment. This study has implications for 39 
development of interventions targeted at reducing the prevalence of IR through modifiable 40 
lifestyle factors, particularly in individuals who harbor the ε4 allele. 41 
 42 
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1. Introduction  62 
Epidemiological studies have provided mounting evidence that insulin resistance (IR) is 63 
associated with an increased risk for Alzheimer’s disease (AD) (Arvanitakis et al., 2004; Ott et 64 
al., 1999; Peila et al., 2002; Schrijvers et al., 2010). Over the past fifty years, the rate of type 2 65 
diabetes mellitus (a non-insulin dependent form of diabetes mellitus) has increased alarmingly 66 
with approximately 387 million individuals diagnosed with the disease as of 2014. Recent 67 
evidence indicates that cognitively healthy individuals in late-middle life with higher IR harbor 68 
more AD-like neuropathology (Starks et al., 2014, Willette et al., 2015). Such studies provide 69 
support that IR may be an underlying mechanism driving an increased risk for development of 70 
AD pathology and that neurodegenerative changes can be observed prior to the onset of marked 71 
cognitive or behavioral impairment. While several animal studies suggest a mechanistic link 72 
between IR and neuropathology (for review see de la Monte and Wands, 2005), the effect of IR 73 
on the development of AD pathology among humans remains poorly understood, particularly at 74 
the preclinical stage of the disease. Identification of modifiable risk factors in midlife may be 75 
particularly relevant to individuals who harbor known genetic risk factors for AD (e.g., APOE 76 
ε4) or who have parental family history of AD. Provided the increasing prevalence of Type 2 77 
diabetes and a growing incidence of dementia, elucidation of neuropathologic processes that 78 
arise from IR that may be associated with increased risk of AD is of paramount importance.  79 
 80 
Efficient utilization of insulin by neurons underlies normal cellular and cognitive function. 81 
Insulin signaling regulates processes critical for neuronal survival and synaptic plasticity 82 
moderating processes such as glucose uptake and energy production through glucose oxidation 83 
(Cersosimo and DeFronzo, 2006). A growing body of evidence has shown that insulin plays an 84 
integral role in learning and memory by modulating excitatory and inhibitory receptors such as 85 
glutamate and GABA receptors, respectively (see Zhao et al., 2004a). Insulin homeostasis is 86 
believed to be an instrumental component in signal transduction cascades that underlie memory 87 
consolidation and long-term memory function (Cardoso et al., 2009; Zhao et al., 2004a; Zhao 88 
and Aklon 2001). It is suspected that brain regions dense with insulin receptors, such as the 89 
medial temporal and frontal lobes, are preferentially sensitive to insulin signaling. Interestingly, 90 
frontal and medial temporal lobe regions, particularly the hippocampus, are some of the first to 91 
be adversely affected in AD (Craft & Watson, 2004; Henneberg & Hoyer, 1995; Zhao et al., 92 
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2004). Cognitively healthy individuals with reduced peripheral insulin function show subtle 93 
cognitive deficits and reduced cerebral glucose metabolism and diminished cerebrocortical 94 
activity (Baker et al., 2011; Tschritter et al., 2006). Among cognitively intact older adults, 95 
reduced glucose tolerance has been associated with poor memory performance and hippocampal 96 
atrophy (Convit et al., 2003). Further, abnormal glucose metabolism—believed to arise from 97 
desensitization of cerebral insulin receptors—is a core feature of sporadic late-onset AD 98 
(Henneberg & Hoyer, 1995) and a number of human studies have provided evidence for a 99 
linkage between Type 2 diabetes and greater risk for developing AD (Li et al., 2015; Peila et al., 100 
2002). Histology from human postmortem studies has provided evidence that insulin pathways 101 
are severely degraded in AD brains showing a vast reduction in insulin receptor expression and 102 
insulin receptor binding (de la Monte & Tong, 2014). These findings are suggestive of an 103 
integral role of insulin dysfunction in the pathogenesis of AD.  104 
 105 
The proteolytic processing of amyloid precursor protein (APP) is believed to be one of many 106 
neurobiological processes negatively affected by IR that may contribute to AD pathology. APP is 107 
processed by two competing pathways: the amyloidogenic β-secretase-mediated and the 108 
nonamyloidogenic α-secretase-mediated pathways. Cleavage of APP by α-secretase is thought to 109 
mitigate the formation of extracellular amyloid plaques by preventing the formation of amyloid 110 
beta (Aβ). APP processed through the α-secretase pathway is cleaved within the Aβ sequence 111 
producing soluble peptides (Nunan and Small, 2000). By contrast, APP cleavage by β-secretase 112 
produces sAPP-β that consequently results in generation of Aβ peptides by endoproteolytic 113 
processing (Vassar et al., 1999). In the β-secretase pathway cleavage by γ-secretase adjacent to 114 
residue 42 is the last step in formation of the 42 amino acid species Aβ42. Among the Aβ 115 
peptides, Aβ42 is implicated in the production and proliferation of amyloid plaques that arise 116 
from the aggregation and oligomerization of Aβ42.  Amyloid plaques are a hallmark of AD 117 
pathology and amyloidogenic processes such as Aβ42 oligomerization is suspected to be involved 118 
in neuronal dysfunction and cell death. Over the past decade a number of studies have provided 119 
evidence that Aβ42 oligomers have neurotoxic effects that include degradation of synaptic 120 
structure (Lacor et al., 2004, 2007) and disruption of molecular and cellular mechanisms integral 121 
to memory formation such as synaptic transmission and plasticity (Rowan et al., 2003; Shankar 122 
et al., 2008; Lambert et al., 1998). Transgenic mouse models provide evidence that IR promotes 123 
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activation of the amyloidogenic pathway via cleavage of amyloid precursor protein by β-124 
secretase (sAPP-β) (Farris et al., 2003; Gasparini et al., 2001) and that overproduction of sAPP-β 125 
is associated with disrupted synaptic transmission and plasticity in the hippocampus (Rowan et 126 
al., 2003). Congruent with these findings, a study of diet-induced IR in Tg2576 transgenic mice 127 
showed that IR promoted amyloidogenic Aβ production, increased AD-type amyloid plaque 128 
burden, and impaired performance on hippocampal-dependent memory tasks (i.e., allocentric 129 
spatial water maze) (Ho et al., 2004).  130 
 131 
Other risk factors for AD include non-modifiable risk factors such as genetic risk, parental 132 
family history of AD and age. It is known that carriage of one or two ε4 alleles of apolipoprotein 133 
E (APOE ε4) is a major genetic risk factor for AD. Several studies on asymptomatic APOE ε4 134 
carriers compared to non-carries have provided evidence that ε4 allele carriers harbor features 135 
characteristic of AD pathology such as hypometabolism (Reiman et al., 2004, 2005; Small et al., 136 
2000), higher amyloid burden (Corder et al., 1993) and gray matter atrophy in AD-sensitive 137 
regions (Lemaitre el a., 2005). Animal studies have provided evidence that APOE ε4 carriage 138 
may be particularly deleterious to the hippocampus showing that APOE ε4 mice are impaired on 139 
hippocampal-dependent tasks such as the Morris Water Maze, object recognition and context 140 
fear conditioning (Salomon-Zimri et al., 2013). Thus APOE ε4 has been implicated in several 141 
AD-relevant pathways, including amyloid accumulation, brain hypometabolism and gray matter 142 
degradation.  143 
 144 
Several studies have shown that asymptomatic late-midlife individuals with parental family 145 
history of AD (FH+) show early pathological changes in AD-sensitive regions (Adluru et al., 146 
2014; Honea et al., 2010, 2011; Johnson et al., 2006, 2014; Mosconi et al., 2010; Okonkwo et al., 147 
2012). Neurodegeneration and neuropathology observed in these individuals is consistent with, 148 
although substantially less severe, pathology observed in mild cognitive impairment (MCI) and 149 
AD patients. As genetic and familial risk factors are invariable, modifiable behaviors that may 150 
decrease the risk of developing AD are of clinical interest. Development of intervention-based 151 
strategies aimed at preventing or reversing IR in midlife may help to significantly reduce one’s 152 
risk of incipient neuropathological changes that may underlie or contribute to the 153 
etiopathogenesis of AD.  Midlife is a critical time period during which lifestyle factors that 154 
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confer risk for AD may be altered. While carriage of the ε4 allele and parental family history of 155 
AD are known to increase Alzheimer’s disease risk moderating effects of these factors on 156 
molecular mechanisms alone are not sufficient to cause the disease. 157 
 158 
To investigate the association between IR and AD pathology observed in healthy middle-aged 159 
adults enriched for AD [i.e. parental family history of AD (FH+)], the current study examined 160 
the effect of IR on cerebrospinal fluid (CSF) biomarkers of AD and a hippocampal-dependent 161 
memory task (i.e., delayed recall). Specifically we examined the effects of IR and APOE ε4 162 
status on CSF sAPP-β, Aβ42, P-tau181 and P-tau181/Aβ42, and performance on the Rey Auditory 163 
Verbal Learning Test (RAVLT), delayed recall. APOE ε4 status was also examined as an 164 
invariable risk factor for AD pathology in midlife.  We hypothesized that both IR and APOE ε4 165 
would be associated with 1) increased CSF biomarkers of neural injury and amyloid burden and 166 
2) decreased memory performance. Given prior studies showing that the effects of IR may 167 
depend on APOE ε4 carriage, we also tested for interactions between IR and APOE ε4 on CSF 168 
biomarkers and memory function.  169 
  170 
 2. Methods and Materials  171 
2.1. Participants  172 
The current study examined 70 asymptomatic middle-aged adults (mean age= 57.7 years, SD= 173 
5.11, range= 46-66, 78.6% female) from the Wisconsin Alzheimer’s Disease Research Center 174 
(ADRC) Investigating Memory in People At risk, Causes and Treatments (IMPACT) cohort 175 
(Table 1). All participants had a parental family history of sporadic AD (FH+) defined as one or 176 
both biological parents meeting AD clinical diagnosis criteria (McKhann et al., 1984, 2011). 177 
Parental family history was determined by a validated interview reviewed by a multidisciplinary 178 
diagnostic consensus panel (Kawas et al., 1994) or postmortem neuropathological diagnosis of 179 
AD. Individuals underwent lumbar puncture, fasting blood draw and comprehensive 180 
neuropsychological testing. Inclusion criteria entailed no history of a clinical diagnosis of 181 
diabetes or current diabetes treatment. Fasting plasma glucose (FPG) was evaluated to exclude 182 
individuals who met FPG criteria for diabetes diagnosis (i.e. FPG > 125 mg/dL). All participants 183 
were required to have normal cognitive function, as determined by neuropsychological 184 
evaluation and consensus review, and no current diagnosis of major psychiatric illness. 185 
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Participants were defined as APOEε4 positive if they harbored at least one copy of the ε4 allele. 186 
Hetero- and homozygous ε4 allele carriers constituted 47% of the sample. 187 
 188 
2.2. Design and Procedure  189 
To assess insulin resistance and biomarkers of CSF AD pathology, venous blood and CSF were 190 
collected in the morning after a 12h fast. Blood samples were collected in 9ml polypropylene 191 
tubes, allowed to clot for 30mins and centrifuged at 4*C at 3000 rpm for 10mins. Cell-free 192 
plasma/serum was aliquoted into 1.5mL micro centrifuge tubes and frozen at -80 degrees 193 
Celsius. Plasma and serum samples were analyzed at the University of Wisconsin Hospital and 194 
Clinics Hospital Laboratory (Madison, WI). To assess fasting glucose, plasma was assayed using 195 
hexokinase glucose method (Siemens Dimension Vista). To assess fasting insulin, serum was 196 
assayed using chemiluminescent immunoassay on an ADVIA Centaur XP Immunoassay System 197 
(Siemens Corporation, Washington DC, USA). Insulin resistance was calculated from fasting 198 
serum insulin and fasting plasma glucose using the homeostatic model assessment of insulin 199 
resistance (HOMA-IR) method (Matthews et al., 1985) calculated as HOMA-IR = Insulin 200 
(mg/dL) x Glucose (uIU/mL) / 405. 201 
 202 
CSF was collected through gentle extraction via lumbar puncture using a Sprotte 25- or 24-gauge 203 
spinal needle at the L3/4 or L4/5 level of the spinal column. Approximately 22mL of CSF was 204 
extracted, gently mixed and centrifuged at 2000g for 10mins. Supernatants were frozen in 205 
polypropylene tubes in 0.5mL aliquots and stored at -80 degrees Celsius. CSF was assayed for P-206 
tau181 and A42 using commercially available enzyme-linked immunosorbent assay (ELISA) 207 
methods (INNOTEST assays, Fujiurebio, Ghent Belgium) as previously described in detail 208 
(Palmqvist et al., 2014). CSF sAPP- was measured using the MSD Multiplex Soluble APP 209 
assay (Meso Scale Discovery, Rockville, MD), as described by the manufacturer. Board-certified 210 
laboratory technicians blinded to clinical information analyzed all samples in accordance to 211 
protocols approved by the Swedish Board of Accreditation and Conformity Assessment 212 
(SWEDAC). One batch of reagents was used yielding intra-assay coefficients of <10 % 213 
variation. The P-tau181/Aβ42 ratio was examined as a marker of multiple pathological processes 214 
that occur in AD. 215 
 216 
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APOE ε4 status was determined using genetic testing by the Wisconsin Alzheimer’s Disease 217 
Research Center. Genotyping was performed using non-fasting blood sample collected at 218 
baseline visit, using standard polymerase chain reaction (PCR) and deoxyribonucleic acid (DNA) 219 
sequencing techniques. DNA extracted from whole blood was genotyped with the use of a 220 
homogenous Florescent Resonance Energy Transfer technology coupled to competitive allele 221 
specific PCR (LGC Genomics; Beverly, MA). The National Cell Repository for Alzheimer’s 222 
disease (NCRAD) also performed genotyping. There was 100% concordance for APOE 223 
genotyping between these analyses.  224 
 225 
Participants underwent a comprehensive neuropsychological battery that included the Rey 226 
Auditory Verbal Learning Test (RAVLT) (Rey, 1941) a widely used and well-validated 227 
assessment of memory function. The delayed component of the RAVLT is designed to examine 228 
long-term memory function and is a well-known measure that assesses cognitive changes from 229 
intact, to MCI to AD patients (Estevez-Gonzalez et al., 2003; Ewers et al., 2012). In the current 230 
study the RAVLT delayed task was chosen as a focal index of long-term hippocampal-dependent 231 
memory function.  232 
 233 
2.7. Statistical Analyses  234 
Linear regression analyses were conducted in SPSS (Version 21.0). Analyses tested main effects 235 
of IR as indexed by HOMA-IR and APOE ε4 status, and the interaction between HOMA-IR and 236 
APOEε4 on CSF biomarkers of AD and memory performance. A secondary analysis tested the 237 
interaction between HOMA-IR and CSF biomarkers of AD on delayed memory performance. Age, 238 
sex and body mass index (BMI) were included as covariates in all analyses. Education was added 239 
as a covariate in analyses that included neuropsychological test measures (i.e., RAVLT delayed) 240 
as a dependent variable.  241 
 242 
3. Results 243 
3.1. HOMA-IR, APOE ε4 and CSF biomarkers of AD 244 
Linear multiple regression analysis revealed that HOMA-IR and APOE ε4 status were significant 245 
predictors of CSF sAPP-β. Higher HOMA-IR was significantly associated with increased levels 246 
of CSF sAPP-β (F[1,63] = 4.21, p = 0.044) (Figure 1). Further, carriage of the ε4 allele significantly 247 
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predicted higher levels of CSF sAPP-β (F[1,63] = 7.74, p  = 0.007) (Figures 2). The interaction 248 
between HOMA-IR and APOE ε4 on CSF sAPP-β was not significant.  249 
Significant relationships between CSF Aβ42 and predictor variables and CSF P-tau181 and predictor 250 
variables were not found, however, a significant effect of APOE ε4 status on the ratio of CSF P-251 
tau181/Aβ42 was observed (F[1,63] = 5.21, p = 0.026). CSF P-tau181/Aβ42 was significantly greater in 252 
APOE ε4 carriers compared to non-carriers (Figure 3).  253 
 254 
3.2. HOMA-IR, APOE ε4, CSF biomarkers of AD and Memory Performance  255 
To investigate independent and concomitant effects of IR, genetic risk and AD pathology on 256 
memory function, HOMA-IR, APOE ε4 and P-tau181/Aβ42 were examined with respect to delayed 257 
memory score on the RAVLT. Analyses yielded a significant interaction between HOMA-IR and 258 
P-tau181/Aβ42 on memory performance (F[1,60] = 6.14, p = 0.016). Higher HOMA-IR and greater 259 
P-tau181/Aβ42 predicted impaired delayed memory performance (Figure 4). No other significant 260 
interactions were observed.  261 
 262 
4. Discussion  263 
IR is associated with an increased relative risk for developing sporadic late-onset AD. 264 
Dysregulation of insulin signaling is thought to contribute to a cascade of neuropathological 265 
changes that promote amyloidogenic processing, neurotoxicity, and brain amyloidosis (Devi et 266 
al., 2012; Henneberg and Hoyer, 1995; Ho et al., 2004; Willette et al., 2015; Zhao et al., 2009). 267 
Brain changes associated with IR that may underlie or contribute to the pathogenesis of AD are 268 
poorly understood, particularly in midlife prior to clinical disease onset. IR is a modifiable risk 269 
factor and thus regulation of normal insulin signaling is an important target for early 270 
intervention, one that may be particularly relevant to persons who harbor genetic risk or have a 271 
parental family history of AD. The current study aimed to investigate the relationship between 272 
IR, AD pathology and memory performance in middle-aged individuals enriched for AD. As a 273 
subsidiary aim, we examined APOEε4 genotype relative to IR, AD pathology and memory 274 
function, as it is a well-established genetic risk factor for AD.  275 
 276 
Our findings revealed that higher IR and carriage of the ε4 allele were both predictors of 277 
increased sAPP-β in CSF, suggesting preferential cleavage of APP through the amyloidogenic β-278 
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secretase pathway. Evidence from animal studies shows that IR promotes amyloidogenic β-279 
amyloid peptide production and upregulated levels of β-site APP cleaving enzyme 1 (BACE1), a 280 
process that generates Aβ42 (Devi, et al., 2012). Although higher IR was associated with an 281 
increase in sAPP-β, a relationship between IR and Aβ42 was not observed. It is known that 282 
cleavage of APP through the β-secretase pathway results in the formation of sAPP-β and the 283 
eventual generation and deposition of Aβ. While the generation of Aβ42 is complex and the 284 
relationship between sAPP-β and Aβ42 is not 1:1, a reasonable prediction would be that an 285 
association between higher IR and increased levels of sAPP-β would yield an inverse 286 
relationship between IR and Aβ42. Prior research from our group has shown that IR predicts brain 287 
amyloid deposition in late middle-aged adults at risk for AD as indexed by [C-11] Pittsburg 288 
compound B (PiB) positron emission tomography (Willette et al., 2015). Given that we did not 289 
find an effect of IR on Aβ42, one could postulate that in the case of IR, Aβ42 is overproduced and 290 
begins depositing in the brain but mechanisms of clearance through the CSF remain intact and 291 
appear to be within normal range during subclinical stages of the disease. The participants 292 
studied here were also younger than in Willette et al (2015).  Longitudinal follow-up on CSF and 293 
amyloid-PET will provide further information for mapping out longitudinal trajectories of 294 
amyloid deposition.   295 
 296 
IR may also be linked to pathological processes via amyloidosis by decreasing availability of 297 
insulin-degrading enzyme (IDE), a large zinc-binding protease that binds to and degrades insulin. 298 
IDE preferentially binds to insulin but also has an affinity for Aβ proteins. In the absence of IR, 299 
IDE is available to bind to and degrade Aβ proteins. In the case of IR, IDE preferentially binds to 300 
the elevated levels of insulin as it aggregates in extracellular space, resulting in less availability 301 
for IDE to be allocated toward degradation of Aβ proteins. Excess amyloid peptides 302 
consequently lead to the formation of amyloid plaques, brain degeneration and neuronal 303 
dysfunction. Animal studies have provided evidence that selective removal of the IDE gene 304 
results in more than a 50% decrease in Aβ degradation and a significant increase in Aβ 305 
deposition (Farris et al., 2003; Ho et al., 2004). Transgenic mouse models of IR have provided 306 
evidence that IDE may not only be affected by IR through interference of IDE-mediated 307 
degradation of Aβ but may also decrease IDE expression and activity (Ho et al., 2004). Further, 308 
recent research has provided evidence that IDE also degrades sAPP-β in the intracellular domain 309 
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(Edbauer et al., 2002) and that elevated levels of sAPP-β were observed in homozygous deletions 310 
of the IDE gene (Farris et al., 2003). These results are aligned with the notion that IR may lead to 311 
increased leaves of sAPP-β through mechanisms that involve diminished IDE availability and 312 
reduced sAPP-β degradation.   313 
 314 
Carriage of the 4 allele of APOE was also a significant predictor of CSF markers of AD 315 
pathology. APOE ε4 status showed a positive relationship with sAPP-β and the ratio of P-316 
tau181/Aβ42 although significant relationships between APOE ε4 carriage and Aβ42 or P-tau181 317 
were not observed. These results validate the notion that P-tau181/Aβ42 may be a more sensitive 318 
index of AD pathology in preclinical populations compared to a single marker of disease and 319 
provide further evidence that multiple pathological processes associated with AD occurs at a 320 
subclinical threshold in asymptomatic midlife persons, particularly ε4 allele carriers.  APOE ε4 321 
status is a strong predictor of AD pathology and is believed to act on the Aβ pathway, leading to 322 
a reduction in clearance and increased Aβ aggregation and deposition (Schmechel et al., 1993). 323 
Our findings provide further support that ε4 allele carriage is associated with AD pathology, and 324 
extends these findings to increased upstream amyloidogenic processing (i.e., sAPP-β) in healthy 325 
middle-aged persons enriched for a family history of AD.  326 
 327 
Interestingly, we found that high IR and P-tau181/Aβ42 concomitantly act to impair memory 328 
performance on the RAVLT delayed memory. Long-term memory tasks—such as the one 329 
examined here—are dependent on the hippocampus, a medial temporal lobe structure negatively 330 
affected by IR (Benedict et al., 2012; Rasgon et al., 2011; Stranahan et al., 2008) and among the 331 
first regions to show structural and functional changes in AD (Convit et al., 2000; Du et al., 332 
2001; Pennanen et al., 2004, Wang et al., 2006). Research from our group has shown that IR in 333 
midlife is associated with hypometabolism in brain regions involved in episodic memory, 334 
including the hippocampus (Willette et al., 2015). Taken together, our findings suggest that 335 
dysregulation of the insulin system in midlife may have deleterious effects on functional 336 
integrity of the hippocampus that precede or act in concert with early pathological AD changes 337 
leading to subclinical memory dysfunction. It is worth noting that while we found that high IR 338 
and AD pathology interacted to impair memory function, we did not observe an interaction with 339 
ε4 allele carriage. This finding suggests that while AD pathology is more prominent in APOE ε4 340 
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carriers in midlife, the combined deleterious effects of IR and AD pathology on memory 341 
performance is observed across carriers and non-carriers alike.  342 
Overall, our findings provide evidence that pathological processes associated with AD are 343 
observed early in aging, prior to the onset of memory difficulty or manifestation of clinically 344 
significant symptoms of cognitive impairment. IR and carriage of the ε4 allele are predictors of 345 
early changes in AD-related CSF biomarkers in persons enriched for parental history of late-346 
onset sporadic AD. We show that IR and AD pathology interact to impair long-term memory 347 
function in middle age. IR is a modifiable risk factor that may be corrected with targeted 348 
interventions. Insulin homeostasis plays an integral role in maintaining healthy neuronal 349 
function, normal cerebral glucose metabolism and reducing or ameliorating pathological 350 
processes associated with AD. Targeted interventions designed to maintain normal insulin 351 
signally may be particularly affective in delaying or ameliorating AD disease onset in persons 352 
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Include sAPP-beta, Abeta42 and P-tau data in this table, and perhaps also have another 































Figure 1. Association between HOMA-IR (log) and CSF sAPP-β across all participants. Units 























Figure 2. Comparison of CSF sAPP-β in APOEε4 carriers compared to non-carriers. Error bars 





















Figure 3. Comparison of CSF P-tau181/Aβ42 in APOEε4 carriers compared to non-carriers. Error 




















Figure 3. Comparison of CSF P-tau181/Aβ42 in APOEε4 carriers compared to non-carriers. Error 
bars designate standard error of the mean. *Significant at p < 0.01.  
Figure 4. Interaction between HOMA-IR and CSF P-tau181/Aβ42 on delayed memory 
performance. Memory performance was adjusted for sex, age and education. Shown as the 
median split of HOMA-IR(log). Individuals with lower IR are shown in blue. Individuals with 
higher IR are shown in green.  
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